GPR119 Agonists for Glucose-Dependent Insulin Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes and related conditions like obesity and metabolic syndrome are inadequate in effectively managing insulin resistance and glucose levels without causing hypoglycemia.
Innovation Solution
Development of novel GPR119 agonists, specifically compounds represented by a specific formula and their pharmaceutically acceptable salts, which enhance insulin release from pancreatic islets in response to elevated glucose levels, thereby improving glucose tolerance and weight loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for type 2 diabetes are used to manage insulin resistance and glucose levels, then glucose control is improved, but hypoglycemia is caused
Solution Approach 1:
The patent applies parameter changes by developing novel GPR119 agonist compounds with specific molecular structures (Formula I) that modify the pharmacological parameters of insulin secretion. These compounds change the glucose-dependent insulin secretion profile, allowing effective glucose control while preventing hypoglycemia through glucose-responsive action mechanisms
Solution Approach 2:
The patent uses GPR119 receptor agonists as intermediary substances that mediate between glucose levels and insulin secretion. These compounds act as molecular mediators that enhance endogenous insulin release in a glucose-dependent manner, providing a safe intermediary mechanism that avoids direct insulin administration and its associated hypoglycemia risk
2Reliability
If GPR119 agonists are developed to enhance insulin release, then glucose tolerance is improved, but compound specificity and selectivity must be maintained
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features at different positions of the molecular scaffold. The substituents R1-R6 at various positions provide localized functional properties that ensure selective binding to GPR119 receptor while maintaining glucose-dependent insulin secretion, achieving both efficacy and specificity
Solution Approach 2:
The patent segments the molecular structure into distinct functional regions with specific substituents (R1-R6 groups) that can be independently optimized. This segmentation allows separate optimization of pharmacodynamic properties (glucose tolerance enhancement) and pharmacokinetic properties (specificity and selectivity)
Data Source
AI summary
Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.